Journal of Nutrition Review (June 20): 'Avoiding Malnutrition in the Era of GLP-1 Medications' — 25% of GLP-1 Weight Loss is Lean Mass, Calls for Protein Standards and Routine Body-Composition Endpoints in Late-Stage Trials
The Journal of Nutrition published online on June 20, 2026 a review titled 'Avoiding malnutrition in the era of GLP-1 medications: emerging evidence and opportunities for integrated nutrition care.' The review documents that approximately 25% of total weight lost on GLP-1 therapy is lean mass — a substantial proportion depending on the magnitude of weight reduction achieved — and frames disproportionate fat-free mass loss as a metabolic-health and physical-function risk independent of total weight loss. The authors call for GLP-1-specific randomized trials defining optimal protein intake stratified by age, rate of weight loss, and baseline sarcopenia risk; guidance on when supplementation may be necessary; strategies for monitoring micronutrient status; and routine incorporation of body composition assessments (DXA/BIA) and standardized muscle function measures (handgrip strength, chair-rise testing) as co-primary or key secondary endpoints in future GLP-1 RA studies.